書籍詳細

◆ 第1章 : フィブラートの幅広い使い方

P.12 掲載の参考文献

• 1) Sasai K et al. Human cholesteryl ester transfer protein measured by enzyme-linked immunosorbent assay with two monoclonal antibodies against rabbit cholesteryl ester transfer protein:plasma cholesteryl ester transfer protein and lipoproteins among Japanese hypercholesterolemic patients. Clin Chem 1998;44:1466-1473.
  pubmed

• 2) Goto A et al. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects:a study based on coronary angiography. Atherosclerosis 2001;159:153-163.
  pubmed

• 3) Yamamoto A et al. Life style and cardiovascular risk factors in the Japanese population-from an epidemiological survey on serum lipid levels in Japan 1990 part 1:influence of life style and excess body weight on HDL-cholesterol and other lipid parameters in men. J Atheroscler Thromb 2003;10:165-175.

• 4) Arakawa R et al. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-1-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter AI gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005;25:1193-1197.

• 5) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

P.16 掲載の参考文献

• 1) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準 日本内科学会雑誌 2005; 94: 794-809.

• 2) Lamarche B et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 2001;17:859-865.

• 3) Vakkilainen J et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease:the Diabetes Atherosclerosis Intervention Study(DAIS) . Circulation 2003;107:1733-1737.
  pubmed

• 4) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

P.21 掲載の参考文献

• 1) Eto M et al. Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan. Clin Genet 2002;61:416-422.
  pubmed

• 2) Saito M, Eto M. Accelerated nephropathy in type 2 diabetic patient with type III hyperlipoproteinemia(apoE 2/2 genotype) and the detrimental effects of their remnant lipoproteins on human mesangial cells. Diabetologia(Suppl.1) 2007;50:31-32.

• 3) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) : randomised controlled trial. Lancet 2005;366:1849-1861.

• 4) Nordestgaard BG et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
  pubmed

• 5) Saito M et al. Effectiveness and safety of rosuvastatin administration in type 2 diabetic patients with hypercholesterolemia. Jpn Pharmacol Ther 2007;35:1077-1083.

• 6) Saito M et al. Effectiveness and safety of ezetimibe monotherapy in hyperlipidemic patients-ezetimibe reduces plasma remnant cholesterol-. Jpn Pharmacol Ther 2008;36-411-416.

P.25 掲載の参考文献

• 1) 日本動脈硬化学会. 動脈硬化性疾患予防ガイドライン2007年版.
  Medical*Online

• 2) Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.

• 3) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

P.29 掲載の参考文献

• 1) http://www.diabetes.org/for-health-professionals-and-scientists/cardiometabolic-risk.jsp

• 2) Liberopoulos EN et al. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005;6:283-296.
  pubmed

• 3) 島袋充生. メタボリックシンドロームと脂肪毒性. 日本内科学会雑誌 2006; 95: 1721-1725.

P.33 掲載の参考文献

• 1) Farnier M et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897-905.
  pubmed

• 2) McKenney JM et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-1587.
  pubmed

P.38 掲載の参考文献

• 1) Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978;40:1069-1118.

• 2) Frick MH et al. Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
  pubmed

• 3) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

• 4) 梶山梧朗ほか. GRS-001 (fenofibrate) のヒト胆汁脂質に与える影響について. Prog Med 1995; 15(Suppl 1) : 1037-1045.

P.43 掲載の参考文献

• 1) Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.

• 2) McKenney JM et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-1587.
  pubmed

• 3) Ikewaki K et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men-anuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278-285.

• 4) Despres JP et al. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels:a 12-week randomized trial. J Intern Med 2002;251:490-499.

◆ 第2章 : フィブラートの新たなエビデンス

P.49 掲載の参考文献

• 1) 井上郁夫. エネルギー代謝に関する転写因子の役割-PPARα. Mebio 2004; 21: 9-20.

• 2) Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
  pubmed

• 3) Fruchart JC et al. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83-92.
  pubmed

• 4) Inaba T et al. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in lowdensity lipoprotein receptor knockout mice. Hypertens Res 2008;31:999-1005.
  pubmed

• 5) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

P.54 掲載の参考文献

• 1) Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals:a randomised placebo-controlled trial. Lancet 2002;360:7-22.

• 2) Frick MH et al. Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
  pubmed

• 3) Rubins HB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.

• 4) The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27.

• 5) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

P.58 掲載の参考文献

• 1) 中野早紀子ほか. 糖尿病網膜症の病期と治療. カレントテラピー 2006; 24(11) : 938-942.

• 2) PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-2230.
  pubmed

• 3) Chaturvedi N et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.

• 4) Keech AC et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study) :a randomized controlled trial. Lancet 2007;370(9600) :1687-1697.
  pubmed

P.63 掲載の参考文献

• 1) Fruchart JC et al. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83-92.
  pubmed

• 2) Fruchart JC et al. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245-257.
  pubmed

• 3) Chinetti G et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000;101:2411-2417.
  pubmed

• 4) Ji Y et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997;272:20982-20985.
  pubmed

• 5) Rubins HB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.

• 6) Robins SJ et al. Relation of gemfibrozil treatment and lipid levels with major coronary events:VA-HIT:a randomized controlled trial. JAMA 2001;285:1585-1591.
  pubmed

• 7) The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) randomised controlled trial. Lancet 2005;366:1849-1861.

P.67 掲載の参考文献

• 1) Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005;95:120-122.
  pubmed

• 2) Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes:evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006;5:145-156.

• 3) The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

• 4) Grundy SM et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia(the SAFARI trial) . Am J Cardiol 2005;95:462-468.
  pubmed

• 5) ACCORD(http://www.accordtrial.org/public/index.cfm)

◆ 特別対談

P.91 掲載の参考文献

• 1) JDCS 8年次中間報告

• 2) 動脈硬化性疾患予防ガイドライン 2007年度版: 15-18

• 3) 河盛隆造. 日本糖尿病学会ハーゲドーン賞受賞講演:"糖の流れ"における肝・糖取り込み率制御因子の解明. 糖尿病 2006; 49: 771-775.

• 4) Tamura Y et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:3191-3196.
  pubmed

• 5) Sato F et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007;92:3326-3329.
  pubmed

• 6) Schoonjans K et al. The peroxisome proliferator activated receptors(PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109.
  pubmed

• 7) Schoonjans K et al. Role of the peroxisome proliferator-activated receptor(PPARs) in mediating the effects of fibrates and fatty acid on gene expression. J Lipid Res 1996;37:907-925.
  pubmed

• 8) Uchino H et al. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes:assessment using nateglinide, a new insuhn secretagogue. Endocr J 2000;412:639-641.

• 9) Kawai J et al. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment. Biochem J 2008;412:93-101.
  pubmed

• 10) Keech AC et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study) :a randomised controlled trial. Lancet 2007;370:1687-1697.
  pubmed

• 11) 山下 毅. フェノフィブラート. 日本臨牀 2001; 59 (増刊号3) : 618-624

• 12) Tsimihodimos V et al. Fenofibrate:metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87-98.
  pubmed

• 13) 笠山宗正ほか. PPARαリガンドであるフェノフィブラートの血管におけるpleiotropic effect-抗炎症作用, 血管内皮細胞に及ぼす効果を踏まえて-.
  Medical*Online

• 14) The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention(BIP) study. Circulation 2000;102:21-27.

• 15) Idzior-Walus B et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000;30:871-878.
  pubmed

• 16) 島袋充生. メタボリックシンドロームと脂肪毒性. 日本内科学会雑誌 2006; 95: 1721-1725.

• 17) Keech A et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) :randomised controlled trial. Lancet 2005;366:1849-1861.

• 18) Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-1366.
  pubmed

• 19) Kim J et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007;84:886-893.
  pubmed

• 20) Malik J et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia(fenofibrate versus atorvastatin trial-FAT) . Cardiovasc Res 2001;52:290-298.
  pubmed

• 21) Ryan KE et al. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Atherosclerosis 2007;194:e123-130.

• 22) Skrha J et al. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol 2004;493:183-189.
  pubmed

• 23) Iwashita N et al. lmpaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. Diabetologia 2007;50:380-389.
  pubmed

• 24) Nakajima K et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care 2003;26:892-898.
  pubmed

• 25) Kawasumi M et al. Strict glycemic control ameliorates the increase of carotid IMT in patients with type 2 diabetes. Endocr J 2006;53:45-50.
  pubmed

• 26) Grundy SM et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia(the SAFARI trial) . Am J Cardiol 2005;95:462-468.
  pubmed

• 27) Koh KK et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-1653.
  pubmed

• 28) Jones PH et al. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005;95:120-122.
  pubmed

• 29) Liuzzo G et al. The prognostic value of C-reactive protein and serum amyloid aprotein in severe unstable angina. N Engl J Med 1994;331:417-424.

• 30) Ridker PM et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844.
  pubmed

• 31) Yasojima K et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-1051.
  pubmed

• 32) Doo YC et al. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris. Am J Cardiol 2004;93:554-558.
  pubmed